<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName journalpublishing.dtd?>
  <?SourceDTD.Version 2.3?>
  <?ConverterInfo.XSLTName jp2nlmx2.xsl?>
  <?ConverterInfo.Version 2?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Curr Clin Pharmacol</journal-id>
      <journal-id journal-id-type="publisher-id">CCP</journal-id>
      <journal-title-group>
        <journal-title>Current Clinical Pharmacology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1574-8847</issn>
      <publisher>
        <publisher-name>Bentham Science Publishers Ltd.</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">2841427</article-id>
      <article-id pub-id-type="pmid">19442077</article-id>
      <article-id pub-id-type="publisher-id">CCP-4-126</article-id>
      <article-id pub-id-type="doi">10.2174/157488409788184972</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Pharmacological Characteristics and Clinical Applications of K201</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kaneko</surname>
            <given-names>Noboru</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="corresp" rid="cor1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Matsuda</surname>
            <given-names>Ryuko</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hata</surname>
            <given-names>Yoshihito</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shimamoto</surname>
            <given-names>Ken</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>Department of Cardiology and Pneumology, Dokkyo Medical University, Tochigi, Japan</aff>
      <aff id="aff2"><label>2</label>Department of Cardiology, Tokyo Women&#x2019;s Medical University, Aoyama Hospital, Tokyo, Japan</aff>
      <author-notes>
        <corresp id="cor1"><label>*</label>Address correspondence to this author at the Department of Cardiology and Pneumology, Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, 321-0293, Japan; Tel: +81 282-86-5692; Fax: +81 282-86-5643; E-mail: <email xlink:href="nkaneko@dokkyomed.ac.jp">nkaneko@dokkyomed.ac.jp</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>5</month>
        <year>2009</year>
      </pub-date>
      <volume>4</volume>
      <issue>2</issue>
      <fpage>126</fpage>
      <lpage>131</lpage>
      <history>
        <date date-type="received">
          <day>10</day>
          <month>7</month>
          <year>2008</year>
        </date>
        <date date-type="rev-recd">
          <day>14</day>
          <month>10</month>
          <year>2008</year>
        </date>
        <date date-type="accepted">
          <day>05</day>
          <month>12</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2009 Bentham Science Publishers Ltd.</copyright-statement>
        <copyright-year>2009</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/">
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<uri xlink:type="simple" xlink:href="http://creativecommons.org/licenses/by/2.5/">http://creativecommons.org/licenses/by/2.5/</uri>), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>K201 is a 1,4-benzothiazepine derivative that is a promising new drug with a strong cardioprotective effect. We initially discovered K201 as an effective suppressant of sudden cardiac cell death due to calcium overload. K201 is a nonspecific blocker of sodium, potassium and calcium channels, and its cardioprotective effect is more marked than those of nicorandil, prazosine, propranolol, verapamil and diltiazem. Recently, K201 has also been shown to have activities indicated for treatment of atrial fibrillation, ventricular fibrillation, heart failure and ischemic heart disease, including action as a multiple-channel blocker, inhibition of diastolic Ca<sup>2+</sup> release from the sarcoplasmic reticulum, suppression of spontaneous Ca<sup>2+</sup> sparks and Ca<sup>2+</sup> waves, blockage of annexin V and provision of myocardial protection, and improvement of norepinephrine-induced diastolic dysfunction. Here, we describe the pharmacological characteristics and clinical applications of K201.</p>
      </abstract>
      <kwd-group>
        <title>Key Words</title>
        <kwd>K201</kwd>
        <kwd>cardiac ryanodine receptor (RyR2)</kwd>
        <kwd>annexin V</kwd>
        <kwd>diastolic heart failure</kwd>
        <kwd>multiple-channel blocker.</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Ischemic heart disease, heart failure and severe arrhythmia still have a poor outcome despite recent advances in drug therapy. These diseases interact with one another and consequently treatment options are often limited. In two large-scale clinical trials, the CAST [<xref ref-type="bibr" rid="R1">1</xref>] and SWORD [<xref ref-type="bibr" rid="R2">2</xref>] studies, performed to assess the effect of antiarrhythmic drugs on myocardial infarction, Vaughan-Williams Class Ic and III drugs aggravated outcome more severely than placebo and limitations of specific single-channel blockers were found.</p>
      <p>K201 [4-[3-(4-benzylpiperidin-1-yl)propionyl]-7-methoxy-2,3,4,5-tetrahydro-1,4-benzothiazepine monohydrochloride; C<sub>25</sub>H<sub>32</sub>N<sub>2</sub>O<sub>2</sub>S&#x2022;HCl; MW: 461.07 (Fig. <bold><xref ref-type="fig" rid="F1">l</xref></bold>)] is a promising new drug that has cardioprotective effects. K201 was initially discovered by Kaneko et al. as an effective suppressant of sudden cardiac cell death (that is, kinetic cell death) for prevention of onset of myocardial infarction [<xref ref-type="bibr" rid="R3">3</xref>]. Kinetic cell death occurs due to myofibrillar overcontraction induced by high intracellular calcium, but not ischemic reperfusion. We first established a screening system for drug discovery using a kinetic cell death model prepared by the Langendorff method. In this model, myofibrillar overcontraction due to excessive Ca<sup>2+</sup> release from the sarcoplasmic reticulum was induced by stimulation of epinephrine and caffeine with Ca<sup>2+</sup> loading. Many compounds were screened using this model, with the resultant discovery of K201 [<xref ref-type="bibr" rid="R3">3</xref>]. </p>
      <p>K201 is a 1,4-benzothiazepine derivative with a different structural scaffold from the 1,5-benzothiazepine, diltiazem, and is not classified as a calcium channel blocker. Rather than acting as a &#x3B2; receptor blocker, K201 blocks &#x3B1;<sub>1</sub> receptors and intracellular Ca<sup>2+</sup> pathways [<xref ref-type="bibr" rid="R3">3</xref>] and has various actions.</p>
      <p>The effects of K201 on the cardiovascular system have been studied extensively and the sites of action of K201 in membranes and intracellular organs in cardiomyocytes are shown in Fig. (<bold><xref ref-type="fig" rid="F2">2</xref></bold>). We note that the drug is currently referred to as K201 or JTV519. K201 was the original name of the compound during development, whereas the drug was referred to as JTV519 in later clinical trials. Here, we describe the pharmacological characteristics and clinical applications of K201. </p>
    </sec>
    <sec>
      <title>PHARMACOLOGICAL CHARACTERISTICS OF K201</title>
      <sec>
        <label>1.</label>
        <title>K201 is a Multiple-Channel Blocker</title>
        <p>K201 is a non-specific blocker of sodium, potassium and calcium channels [<xref ref-type="bibr" rid="R4">4</xref>-<xref ref-type="bibr" rid="R6">6</xref>]. The effect of K201 on membrane current has been studied using the whole-cell voltage-clamp method in isolated guinea pig ventricular myocytes [<xref ref-type="bibr" rid="R4">4</xref>, <xref ref-type="bibr" rid="R5">5</xref>] and in atrial cells [<xref ref-type="bibr" rid="R6">6</xref>]. K201 inhibits the Na<sup>+</sup> current (I<sub>Na</sub>) in a voltage- and frequency-dependent manner with IC<sub>50</sub> values of approximately 1.2 and 2 &#x3BC;M at holding potentials of -60 and -90 mV, respectively. The time-course of I<sub>Na</sub> blocking by K201 is slower than that of lidocaine and similar to that of quinidine; therefore, K201 is categorized as having &#x201C;intermediate&#x201D; but not &#x201C;fast&#x201D; kinetics.</p>
        <p>K201 also slightly blocks the Ca<sup>2+</sup> current (I<sub>Ca</sub>) and the inwardly rectifying K<sup>+</sup> current (I<sub>K1</sub>) with IC<sub>50</sub> values of 3 and 5 &#x3BC;M, respectively. K201 blocks the rapidly activating component of the delayed rectified K<sup>+</sup> current (I<sub>Kr</sub>) with an IC<sub>50</sub> of 1.2 &#x3BC;M [<xref ref-type="bibr" rid="R6">6</xref>], but not the slowly activating component (I<sub>Ks</sub>) [<xref ref-type="bibr" rid="R4">4</xref>-<xref ref-type="bibr" rid="R6">6</xref>]. Recently, Nakaya et al. [<xref ref-type="bibr" rid="R6">6</xref>] also showed inhibitory effects of K201 on the muscarinic acetylcholine receptor-operated K current (I<sub>KAch</sub>), and K201 inhibits the carbachol-, adenosine-, and GTP gamma S-induced I<sub>KAch </sub>with IC<sub>50</sub> values of 0.12, 2.29 and 2.42 &#x3BC;M, respectively [<xref ref-type="bibr" rid="R6">6</xref>]. </p>
      </sec>
      <sec>
        <label>2.</label>
        <title>K201 Inhibits Ca<sup>2+</sup> Release from the Sarcoplasmic Reticulum</title>
        <p>Calcium release from the sarcoplasmic reticulum (SR) is the major source of Ca<sup>2+</sup> required for excitation-contraction (EC) coupling. Membrane depolarization activates the L-type Ca<sup>2+</sup> influx channel, which results in Ca<sup>2+ </sup>influx that then triggers a large Ca<sup>2+</sup> release from the SR by opening the cardiac ryanodine receptor (RyR2). This mechanism is known as Ca<sup>2+</sup>-induced Ca<sup>2+</sup> release [<xref ref-type="bibr" rid="R7">7</xref>]. </p>
        <p> K201 is believed to stabilize the closed state of RyR2 by increasing its affinity for the 12.6 kDa FK506-binding protein (FKBP12.6), which prevents the Ca<sup>2+</sup> leak that triggers arrhythmias [<xref ref-type="bibr" rid="R8">8</xref>]. Protein kinase A (PKA) phosphorylation of RyR2 dissociates FKBP12.6 and regulates channel opening. In failing hearts, RyR2 is hyperphosphorylated by PKA, resulting in defective channel function due to increased sensitivity to Ca<sup>2+</sup>-induced activation [<xref ref-type="bibr" rid="R8">8</xref>-<xref ref-type="bibr" rid="R10">10</xref>]. Hyperphosphorylation of RyR2 in heart failure produced by rapid right ventricular pacing is reversed by K201 treatment, with a return to levels of channel phosphorylation seen in normal hearts. K201 also prevents a decrease in the amount of RyR2-bound FKBP12.6 in this model [<xref ref-type="bibr" rid="R11">11</xref>]. However, recent studies have shown that FKBP12.6 may not be involved in Ca<sup>2+</sup> release from the sarcoplasmic reticulum, since the loss of FKBP12.6 has no significant effect on the conduction and activation of RyR2 or the propensity for spontaneous Ca<sup>2+</sup> release and stress-induced ventricular arrhythmias [<xref ref-type="bibr" rid="R12">12</xref>]. K201 corrects the defective channel gating in RyR2 and causes a rapid conformational change and increased Ca<sup>2+</sup> release in heart failure [<xref ref-type="bibr" rid="R13">13</xref>]. However, it is not clear if this mechanism is associated with FKBP12.6 in terms of channel stabilization of RyR2 [<xref ref-type="bibr" rid="R13">13</xref>]. In a Ca<sup>2+</sup> overload rat model, treatment of ventricular myocytes with FK506 to dissociate FKBP12.6 from RyR2 did not affect the suppression of spontaneous Ca<sup>2+</sup> release by K201 [<xref ref-type="bibr" rid="R14">14</xref>].</p>
        <p>The phosphorylation status of RyR2 in heart failure and its effect on the RyR2-FKBP12.6 interaction are controversial. The PKA-dependent increase in myocyte Ca<sup>2+</sup> spark frequency and size is entirely attributable to phospholamban phosphorylation and consequent enhanced SR Ca<sup>2+</sup> loading, and PKA does not seem to have any appreciable effects on resting RyR2 function in ventricular myocytes [<xref ref-type="bibr" rid="R15">15</xref>]. In cardiac SR vesicles, K201 restores the conformational change and corrects defective channel gating in RyR2 independent of phosphorylation of RyR2 [<xref ref-type="bibr" rid="R13">13</xref>]. FKBP12.6 dissociates from RyR2 due to PKA phosphorylation or FK506-induced domain unzipping, and this causes Ca<sup>2+</sup> leak. K201 reverses this domain unzipping and stops Ca<sup>2+</sup> leak completely, even after FKBP12.6 has mainly dissociated from RyR2 due to hyperphosphorylation of RyR2 [<xref ref-type="bibr" rid="R16">16</xref>]. </p>
      </sec>
      <sec>
        <label>3.</label>
        <title>K201 Suppresses Spontaneous Ca<sup>2+</sup> Sparks (Ca<sup>2+</sup> leak) and Ca<sup>2+</sup> Waves</title>
        <p>In heart muscle, local elevations in intracellular calcium (Ca<sup>2+</sup> sparks) are elementary SR Ca<sup>2+</sup>-release events. A Ca<sup>2+ </sup>spark is a local Ca<sup>2+ </sup>release from the SR that also occurs in normal ventricular myocytes. Ca<sup>2+ </sup>spark accumulation propagates to an adjacent SR as a Ca<sup>2+</sup> wave, with consequent induction of Ca<sup>2+</sup>-induced Ca<sup>2+</sup> release [<xref ref-type="bibr" rid="R17">17</xref>, <xref ref-type="bibr" rid="R18">18</xref>]. In the 48-hour infarcted canine heart, abnormal Ca<sup>2+</sup> wave activity is the underlying cause of afterdepolarization-induced electrical activity in surviving subendocardial Purkinje cells. Drugs that block inward sodium or calcium currents (verapamil, tetrodotoxin) have no effect on Ca<sup>2+</sup> activity in Purkinje cells, but K201 strongly suppresses spontaneous Ca<sup>2+ </sup>release in Purkinje cells dispersed from the subendcardium of the infarct zone (IZPCs) [<xref ref-type="bibr" rid="R19">19</xref>]. Agents that block or inhibit intracellular Ca<sup>2+</sup> channel activity and reduce Ca<sup>2+</sup> waves can have antiarrhythmic effects in arrhythmogenic Purkinje cells in the infarcted heart [<xref ref-type="bibr" rid="R19">19</xref>]. K201 at 1 &#x3BC;mol/L reduces the frequency of spontaneous Ca<sup>2+</sup> release and the frequency and velocity of SR Ca<sup>2+</sup> waves, despite the absence of a change in SR Ca<sup>2+</sup> content, and also reduces Ca<sup>2+</sup> spark amplitude and frequency and inhibits SR Ca<sup>2+</sup> uptake and release. K201 inhibits spontaneous diastolic Ca<sup>2+</sup> release during Ca<sup>2+</sup> overload by a dual inhibitory action on sarcoplasmic reticulum Ca<sup>2+</sup>-ATPase (SERCA2a) and RyR2, without significantly affecting the transient Ca<sup>2+</sup> amplitude [<xref ref-type="bibr" rid="R20">20</xref>]. </p>
      </sec>
      <sec>
        <label>4.</label>
        <title>K201 Blocks Annexin V and Provides Myocardial Protection</title>
        <p>Annexin V is a member of the annexin family of Ca<sup>2+</sup>-binding proteins that have activity that depends on the Ca<sup>2+</sup> concentration. <italic>In vitro</italic>, annexin V binding to F-actin depends on the calcium concentration and the presence of phosphatidylserine, a membrane phospholipid [<xref ref-type="bibr" rid="R21">21</xref>-<xref ref-type="bibr" rid="R23">23</xref>]. K201 inhibits the interaction between these two proteins, whereas diltiazem and KT362 do not inhibit this binding [<xref ref-type="bibr" rid="R3">3</xref>]. Annexin V is distributed in various organs and cells and is involved in processes including fusion, development and differentiation. This protein induces calcium channel activity, as shown by patch-clamping, and is critical in cellular signaling. The crystal structure of annexin V bound to K201 shows that the drug binds in the Ca<sup>2+</sup> &#x201C;hole&#x201D; of annexin V (Fig. <bold><xref ref-type="fig" rid="F3">3</xref></bold>) [<xref ref-type="bibr" rid="R24">24</xref>]. K201 binds in an L-shaped conformation at the hinge region cavity formed by the N-terminal strand and domains II, III and IV, on the side opposite to the calcium and membrane-binding surface (Fig. <bold><xref ref-type="fig" rid="F4">4</xref></bold>(<bold><xref ref-type="fig" rid="F4">a</xref></bold>),(<bold><xref ref-type="fig" rid="F4">b</xref></bold>)). K201 may restrain the hinge movement of annexin V in an allosteric manner, resulting in inhibition of calcium movement across the annexin V molecule [<xref ref-type="bibr" rid="R24">24</xref>]. We have shown that annexin V activates Ca<sup>2+</sup> channels and K201 inhibits this Ca<sup>2+</sup> influx in an artificial lipid membrane. Annexin V also induces Ca<sup>2+</sup> channel activity in large unilamellar vesicles (LUVs) and K201 shows dose-dependent inhibition of annexin V-induced inward Ca<sup>2+</sup> movement into LUVs [<xref ref-type="bibr" rid="R25">25</xref>].</p>
        <p>A recent study has shown a similarity of the amino-acid sequences of RyR2 and annexin V: the K201 binding site in annexin is present as domain 2114-2149 of RyR2, and domain 2059-2156 of RyR2 showed a striking similarity to the corresponding sequence of annexin V [<xref ref-type="bibr" rid="R26">26</xref>]. Interruption of the interdomain interaction between domain 2114-2149 and the central domain 2234-2750 seems to mediate stabilization of RyR2 in failing hearts, and K201 inhibition of Ca<sup>2+</sup> leakage does not depend on the facilitated binding of FKBP12.6 to RyR2 [<xref ref-type="bibr" rid="R26">26</xref>]. Another recent study has shown that annexin V has a site homologous to the &#x3B4; protein kinase C (PKC)-binding protein RACK (receptor for activated C kinase). The RACK-like sequence in annexin V is in close proximity to the K201 binding site on annexin V, which indicates the potential importance of the RACK-like sequence in annexin V for PKC binding. &#x3B4;PKC binding to annexin V activates &#x3B4;PKC translocation, and therefore K201 may inhibit &#x3B4;PKC activity [<xref ref-type="bibr" rid="R27">27</xref>].</p>
      </sec>
      <sec>
        <label>5.</label>
        <title>K201 Improves Norepinephrine-Induced Diastolic Dysfunction</title>
        <p>We have shown that norepinephrine with Ca<sup>2+</sup> loading induces severe diastolic dysfunction [<xref ref-type="bibr" rid="R28">28</xref>]. Under these conditions, a diastolic pressure equivalent to the systolic pressure is induced without membrane depolarization. The left ventricular diastolic pressure is markedly increased and the diastolic pressure exceeds the aortic pressure, resulting in opening of the aortic valve in the diastolic phase (Fig. <bold><xref ref-type="fig" rid="F5">5</xref></bold>) [<xref ref-type="bibr" rid="R28">28</xref>]. K201 significantly inhibits norepinephrine-induced diastolic dysfunction whereas diltiazem has no suppressive effect [<xref ref-type="bibr" rid="R29">29</xref>]. Norepinephrine administration in old myocardial infarction rats induces similar diastolic dysfunction. An intracellular Ca<sup>2+</sup> increase in the diastolic phase is an important factor in development of diastolic dysfunction, but it has also been reported that an intracellular Ca<sup>2+</sup> increase in the diastolic phase alone does not increase the left ventricular end-diastolic pressure [<xref ref-type="bibr" rid="R30">30</xref>].</p>
      </sec>
    </sec>
    <sec>
      <title>CLINICAL APPLICATIONS OF K201</title>
      <sec>
        <label>1.</label>
        <title>Inhibition of Atrial Fibrillation</title>
        <p>K201 inhibits carbachol-induced atrial fibrillation in guinea pig atrial muscle [<xref ref-type="bibr" rid="R6">6</xref>]. An increase in I<sub>KAch</sub> and I<sub>Kr</sub> in atrial muscle cells is a potential mechanism for atrial fibrillation, and I<sub>KAch</sub> is often generated in the sinus node and atrium, and particularly in the atrial appendage of the atrium. K201 directly inhibits I<sub>KAch</sub> [<xref ref-type="bibr" rid="R6">6</xref>] and also inhibits the atrial I<sub>Kr</sub> with an IC<sub>50</sub> of 0.41 &#x3BC;M. Therefore, K201 is thought to improve atrial fibrillation by inhibiting I<sub>KAch</sub> and I<sub>Kr</sub> [<xref ref-type="bibr" rid="R6">6</xref>], and has been shown to inhibit experimental atrial fibrillation in a dog aseptic pericarditis model [<xref ref-type="bibr" rid="R31">31</xref>].</p>
        <p>Abnormal calcium homeostasis with ryanodine receptor dysfunction may underlie arrhythmogenic activity in pulmonary veins. Both pretreatment and rapid administration of K201 (0.3 &#x3BC;M) decrease isoproterenol-induced arrhythmogenesis in pulmonary veins through reduction of the arrhythmogenic activity of pulmonary vein cardiomyocytes. These findings indicate the anti-arrhythmic potential of K201 [<xref ref-type="bibr" rid="R32">32</xref>].</p>
      </sec>
      <sec>
        <label>2.</label>
        <title>Inhibition of Ventricular Tachycardia and Fibrillation</title>
        <p>Triggered activity is a major cause of arrhythmias, in addition to abnormal automaticity and reentry. Triggered activity is classified into early after depolarization (EAD), a transient depolarization that is generated immediately after or from the second or third phase of the preceding action potential; and delayed after depolarization (DAD) generated from the fourth phase of the preceding action potential. EAD develops due to a prolonged duration of the action potential and DAD is induced by an abnormal increase in intracellular Ca<sup>2+</sup>. Classic antiarrhythmic drugs tend to inhibit cardiac function and induce arrhythmia. The class III drug clofilium prolongs QT and induces torsades de pointes (Tdp) and ventricular tachycardia when combined with an &#x3B1;<sub>1</sub>-adrenoceptor stimulator, due to EAD generated from the third phase of the action potential [<xref ref-type="bibr" rid="R33">33</xref>-<xref ref-type="bibr" rid="R35">35</xref>]. We have shown that K201 inhibits clofilium-induced Tdp and attenuates the prolongation of repolarization caused by clofilium. Our results show that K201 causes prolongation of the QT and QTc intervals, but does not induce Tdp, in the presence or absence of &#x3B1;<sub>1</sub>-adrenoceptor stimulation. The inhibition of clofilium-induced Tdp by K201, despite QT prolongation, suggests that QT prolongation alone is not a proarrhythmic signal. K201 suppresses Tdp dose-dependently by blocking the &#x3B1;<sub>1</sub>-adrenoceptor and inhibiting abnormal Ca<sup>2+</sup> release from the SR [<xref ref-type="bibr" rid="R36">36</xref>].</p>
      </sec>
      <sec>
        <label>3.</label>
        <title>Improvement of Diastolic Heart Failure</title>
        <p>Diastolic dysfunction refers to an abnormality in diastolic distensibility, filling, and relaxation of the left ventricle [<xref ref-type="bibr" rid="R37">37</xref>, <xref ref-type="bibr" rid="R38">38</xref>]. The onset mechanism of this type of heart failure, (so-called diastolic heart failure) is unknown. Systolic heart failure can be treated with digitalis and catecholamines that enhance myocardial contractility, but there are no drugs for treatment of diastolic heart failure. We have reported that norepinephrine induces a marked increase in left ventricular end-diastolic pressure in rats with Ca<sup>2+</sup> loading or old myocardial infarction [<xref ref-type="bibr" rid="R28">28</xref>]. K201 significantly suppressed the increase in left ventricular end-diastolic pressure, decreased the incidence of norepinephrine-induced diastolic contracture, including aortic value opening in the diastolic phase, and improved Ea and deceleration time in cardiac Doppler ultrasonography. These results suggest that K201 may be an agent for treatment of diastolic heart failure [<xref ref-type="bibr" rid="R11">11</xref>, <xref ref-type="bibr" rid="R29">29</xref>, <xref ref-type="bibr" rid="R39">39</xref>].</p>
      </sec>
      <sec>
        <label>4.</label>
        <title>Cardioprotective Effects Against Myocardial Injury</title>
        <p>K201 was initially developed as a drug that prevents onset of myocardial infarction and sudden cardiac death. K201 provides myocardial protection more effectively than existing calcium channel blockers and &#x3B2; blockers and is less negatively inotropic and chronotropic [<xref ref-type="bibr" rid="R3">3</xref>]. K201 inhibits ischemia/reperfusion injury dose-dependently [<xref ref-type="bibr" rid="R40">40</xref>] and blocks (Takotsubo) stress cardiomyopathy induced by large amounts of isoproterenol (5 mg/kg) [<xref ref-type="bibr" rid="R41">41</xref>]. K201 also has a cardioprotective effect against myocardial injury that is stronger than those of nicorandil, prazosin, propanolol, verapamil and diltiazem [<xref ref-type="bibr" rid="R3">3</xref>]. These results indicate that K201 can prevent myocardial injury caused by ischemia and catecholamines.</p>
      </sec>
    </sec>
  </body>
  <back>
    <ack>
      <title>ACKNOWLEDGEMENTS</title>
      <p>The authors thank Ms. Miyoko Iwai, Ms. Rie Asaishi and Mr. Masashi Toda for preparation of the manuscript.</p>
    </ack>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="R1">
        <label>1</label>
        <element-citation publication-type="journal">
          <collab>The Cardiac Arrhythmia Suppression Trial (CAST) Investigators</collab>
          <article-title>Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction</article-title>
          <source>N Engl J Med</source>
          <year>1989</year>
          <volume>321</volume>
          <fpage>406</fpage>
          <lpage>412</lpage>
          <pub-id pub-id-type="pmid">2473403</pub-id>
        </element-citation>
      </ref>
      <ref id="R2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Waldo</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Camm</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>deRuyter</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Survival with oral dsotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial)</article-title>
          <source>Am J Cardiol</source>
          <year>1995</year>
          <volume>75</volume>
          <fpage>1023</fpage>
          <lpage>1027</lpage>
          <pub-id pub-id-type="pmid">7747682</pub-id>
        </element-citation>
      </ref>
      <ref id="R3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaneko</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>New 1,4-benzothiazepine derivative, K201, demonstrates cardioprotective effects against sudden cardiac cell death and intracellular calcium blocking action</article-title>
          <source>Drug Dev Res</source>
          <year>1994</year>
          <volume>33</volume>
          <fpage>429</fpage>
        </element-citation>
      </ref>
      <ref id="R4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kimura</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kawahara</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sakai</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Yatabe</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nakanishi</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Effects of a novel cardioprotective drug, JTV-519, on membrane currents of guinea pig ventricular myocytes</article-title>
          <source>Jpn J Pharmacol</source>
          <year>1999</year>
          <volume>79</volume>
          <fpage>275</fpage>
          <lpage>281</lpage>
          <pub-id pub-id-type="pmid">10230854</pub-id>
        </element-citation>
      </ref>
      <ref id="R5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kiriyama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kiyosue</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Dohi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Arita</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Effects of JTV-519, a novel anti-ischaemic drug, on the delayed rectifier K+ current in guinea-pig ventricular myocytes</article-title>
          <source>Naunyn Schmiedebergs Arch Pharmacol</source>
          <year>2000</year>
          <volume>361</volume>
          <fpage>646</fpage>
          <lpage>653</lpage>
          <pub-id pub-id-type="pmid">10882040</pub-id>
        </element-citation>
      </ref>
      <ref id="R6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nakaya</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Furusawa</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ogura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tamagawa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Uemura</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Inhibitory effects of JTV-519, a novel cardioprotective drug, on potassium currents and experimental atrial fibrillation in guinea-pig hearts</article-title>
          <source>Br J Pharmacol</source>
          <year>2000</year>
          <volume>131</volume>
          <fpage>1363</fpage>
          <lpage>1372</lpage>
          <pub-id pub-id-type="pmid">11090108</pub-id>
        </element-citation>
      </ref>
      <ref id="R7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bers</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>Cardiac excitation-contraction coupling</article-title>
          <source>Nature</source>
          <year>2002</year>
          <volume>415</volume>
          <fpage>198</fpage>
          <lpage>205</lpage>
          <pub-id pub-id-type="pmid">11805843</pub-id>
        </element-citation>
      </ref>
      <ref id="R8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wehrens</surname>
              <given-names>XH</given-names>
            </name>
            <name>
              <surname>Lehnart</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Reiken</surname>
              <given-names>SR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2</article-title>
          <source>Science</source>
          <year>2004</year>
          <volume>304</volume>
          <fpage>292</fpage>
          <lpage>296</lpage>
          <pub-id pub-id-type="pmid">15073377</pub-id>
        </element-citation>
      </ref>
      <ref id="R9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marx</surname>
              <given-names>SO</given-names>
            </name>
            <name>
              <surname>Reiken</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hisamatsu</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts</article-title>
          <source>Cell</source>
          <year>2000</year>
          <volume>101</volume>
          <fpage>365</fpage>
          <lpage>376</lpage>
          <pub-id pub-id-type="pmid">10830164</pub-id>
        </element-citation>
      </ref>
      <ref id="R10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wehrens</surname>
              <given-names>XH</given-names>
            </name>
            <name>
              <surname>Marks</surname>
              <given-names>AR</given-names>
            </name>
          </person-group>
          <article-title>Novel therapeutic approaches for heart failure by normalizing calcium cycling</article-title>
          <source>Nat Rev Drug Discov</source>
          <year>2004</year>
          <volume>3</volume>
          <fpage>565</fpage>
          <lpage>573</lpage>
          <pub-id pub-id-type="pmid">15232578</pub-id>
        </element-citation>
      </ref>
      <ref id="R11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yano</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kobayashi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kohno</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure</article-title>
          <source>Circulation</source>
          <year>2003</year>
          <volume>107</volume>
          <fpage>477</fpage>
          <lpage>484</lpage>
          <pub-id pub-id-type="pmid">12551874</pub-id>
        </element-citation>
      </ref>
      <ref id="R12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xiao</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>PP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Removal of FKBP12.6 does not alter the conductance and activation of the cardiac ryanodine receptor or the susceptibility to stress-induced ventricular arrhythmias</article-title>
          <source>J Biol Chem</source>
          <year>2007</year>
          <volume>282</volume>
          <fpage>34828</fpage>
          <lpage>34838</lpage>
          <pub-id pub-id-type="pmid">17921453</pub-id>
        </element-citation>
      </ref>
      <ref id="R13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kohno</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yano</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kobayashi</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A new cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure</article-title>
          <source>Am J Physiol Heart Circ Physiol</source>
          <year>2003</year>
          <volume>284</volume>
          <fpage>H1035</fpage>
          <lpage>1042</lpage>
          <pub-id pub-id-type="pmid">12433661</pub-id>
        </element-citation>
      </ref>
      <ref id="R14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hunt</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>PP</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>K201 (JTV519) suppresses spontaneous Ca2+ release and [3H]ryanodine binding to RyR2 irrespective of FKBP12.6 association</article-title>
          <source>Biochem J</source>
          <year>2007</year>
          <volume>404</volume>
          <fpage>431</fpage>
          <lpage>438</lpage>
          <pub-id pub-id-type="pmid">17313373</pub-id>
        </element-citation>
      </ref>
      <ref id="R15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kranias</surname>
              <given-names>EG</given-names>
            </name>
            <name>
              <surname>Mignery</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Bers</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>Protein kinase A phosphorylation of the ryanodine receptor does not affect calcium sparks in mouse ventricular myocytes</article-title>
          <source>Circ Res</source>
          <year>2002</year>
          <volume>90</volume>
          <fpage>309</fpage>
          <lpage>316</lpage>
          <pub-id pub-id-type="pmid">11861420</pub-id>
        </element-citation>
      </ref>
      <ref id="R16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oda</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yano</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Defective regulation of interdomain interactions within the ryanodine receptor plays a key role in the pathogenesis of heart failure</article-title>
          <source>Circulation</source>
          <year>2005</year>
          <volume>111</volume>
          <fpage>3400</fpage>
          <lpage>3410</lpage>
          <pub-id pub-id-type="pmid">15967847</pub-id>
        </element-citation>
      </ref>
      <ref id="R17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cheng</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Lederer</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Lederer</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Cannell</surname>
              <given-names>MB</given-names>
            </name>
          </person-group>
          <article-title>Calcium sparks and [Ca2+]i waves in cardiac myocytes</article-title>
          <source>Am J Physiol</source>
          <year>1996</year>
          <volume>270</volume>
          <fpage>C148</fpage>
          <lpage>159</lpage>
          <pub-id pub-id-type="pmid">8772440</pub-id>
        </element-citation>
      </ref>
      <ref id="R18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trafford</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>O'Neill</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Eisner</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Factors affecting the propagation of locally activated systolic Ca transients in rat ventricular myocytes</article-title>
          <source>Pflugers Arch</source>
          <year>1993</year>
          <volume>425</volume>
          <fpage>181</fpage>
          <lpage>183</lpage>
          <pub-id pub-id-type="pmid">8272377</pub-id>
        </element-citation>
      </ref>
      <ref id="R19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boyden</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Dun</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Barbhaiya</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ter Keurs</surname>
              <given-names>HE</given-names>
            </name>
          </person-group>
          <article-title>2APB- and JTV519(K201)-sensitive micro Ca2+ waves in arrhythmogenic Purkinje cells that survive in infarcted canine heart</article-title>
          <source>Heart Rhythm</source>
          <year>2004</year>
          <volume>1</volume>
          <fpage>218</fpage>
          <lpage>226</lpage>
          <pub-id pub-id-type="pmid">15851156</pub-id>
        </element-citation>
      </ref>
      <ref id="R20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Loughrey</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Otani</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Seidler</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>K201 modulates excitation-contraction coupling and spontaneous Ca2+ release in normal adult rabbit ventricular cardiomyocytes</article-title>
          <source>Cardiovasc Res</source>
          <year>2007</year>
          <volume>76</volume>
          <fpage>236</fpage>
          <lpage>246</lpage>
          <pub-id pub-id-type="pmid">17644079</pub-id>
        </element-citation>
      </ref>
      <ref id="R21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schlaepfer</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Mehlman</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Burgess</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Haigler</surname>
              <given-names>HT</given-names>
            </name>
          </person-group>
          <article-title>Structural and functional characterization of endonexin II, a calcium- and phospholipid-binding protein</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>1987</year>
          <volume>84</volume>
          <fpage>6078</fpage>
          <lpage>6082</lpage>
          <pub-id pub-id-type="pmid">2957692</pub-id>
        </element-citation>
      </ref>
      <ref id="R22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khanna</surname>
              <given-names>NC</given-names>
            </name>
            <name>
              <surname>Helwig</surname>
              <given-names>ED</given-names>
            </name>
            <name>
              <surname>Ikebuchi</surname>
              <given-names>NW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Purification and characterization of annexin proteins from bovine lung</article-title>
          <source>Biochemistry</source>
          <year>1990</year>
          <volume>29</volume>
          <fpage>4852</fpage>
          <lpage>4862</lpage>
          <pub-id pub-id-type="pmid">2364064</pub-id>
        </element-citation>
      </ref>
      <ref id="R23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kobayashi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Nakayama</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ohta</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Identification of the 32 kDa components of bovine lens EDTA-extractable protein as endonexins I and II</article-title>
          <source>Biochem J</source>
          <year>1990</year>
          <volume>266</volume>
          <fpage>505</fpage>
          <lpage>511</lpage>
          <pub-id pub-id-type="pmid">2138456</pub-id>
        </element-citation>
      </ref>
      <ref id="R24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaneko</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ago</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Matsuda</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Inagaki</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Miyano</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Crystal structure of annexin V with its ligand K-201 as a calcium channel activity inhibitor</article-title>
          <source>J Mol Biol</source>
          <year>1997</year>
          <volume>274</volume>
          <fpage>16</fpage>
          <lpage>20</lpage>
          <pub-id pub-id-type="pmid">9398511</pub-id>
        </element-citation>
      </ref>
      <ref id="R25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaneko</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Matsuda</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Toda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shimamoto</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of annexin V-dependent Ca2+ movement in large unilamellar vesicles by K201, a new 1,4-benzothiazepine derivative</article-title>
          <source>Biochim Biophys Acta</source>
          <year>1997</year>
          <volume>1330</volume>
          <fpage>1</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">9375807</pub-id>
        </element-citation>
      </ref>
      <ref id="R26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamamoto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yano</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Identification of target domains of the cardiac ryanodine receptor to correct channel disorder in failing hearts</article-title>
          <source>Circulation</source>
          <year>2008</year>
          <volume>117</volume>
          <fpage>762</fpage>
          <lpage>772</lpage>
          <pub-id pub-id-type="pmid">18227387</pub-id>
        </element-citation>
      </ref>
      <ref id="R27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kheifets</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Bright</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Inagaki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Schechtman</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mochly-Rosen</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Protein kinase C delta (deltaPKC)-annexin V interaction: a required step in deltaPKC translocation and function</article-title>
          <source>J Biol Chem</source>
          <year>2006</year>
          <volume>281</volume>
          <fpage>23218</fpage>
          <lpage>23226</lpage>
          <pub-id pub-id-type="pmid">16785226</pub-id>
        </element-citation>
      </ref>
      <ref id="R28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaneko</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Matsuda</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Nakajima</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Norepinephrine-induced diastolic dysfunction with aortic valve opening under calcium-loading in rats</article-title>
          <source>Drug Dev Res</source>
          <year>2006</year>
          <volume>67</volume>
          <fpage>511</fpage>
        </element-citation>
      </ref>
      <ref id="R29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaneko</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Matsuda</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ohtani</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>K201 improved norepinephrine-induced diastolic dysfunction with preserved ejection fraction</article-title>
          <source>Drug Dev Res</source>
          <year>2006</year>
          <volume>67</volume>
          <fpage>852</fpage>
        </element-citation>
      </ref>
      <ref id="R30">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eberli</surname>
              <given-names>FR</given-names>
            </name>
            <name>
              <surname>Stromer</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ferrell</surname>
              <given-names>MA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Lack of direct role for calcium in ischemic diastolic dysfunction in isolated hearts</article-title>
          <source>Circulation</source>
          <year>2000</year>
          <volume>102</volume>
          <fpage>2643</fpage>
          <lpage>2649</lpage>
          <pub-id pub-id-type="pmid">11085969</pub-id>
        </element-citation>
      </ref>
      <ref id="R31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kumagai</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nakashima</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Gondo</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Saku</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Antiarrhythmic effects of JTV-519, a novel cardioprotective drug, on atrial fibrillation/flutter in a canine sterile pericarditis model</article-title>
          <source>J Cardiovasc Electrophysiol</source>
          <year>2003</year>
          <volume>14</volume>
          <fpage>880</fpage>
          <lpage>884</lpage>
          <pub-id pub-id-type="pmid">12890053</pub-id>
        </element-citation>
      </ref>
      <ref id="R32">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>YJ</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>YC</given-names>
            </name>
            <name>
              <surname>Wongcharoen</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>CI</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <article-title>Effect of K201, a novel antiarrhythmic drug on calcium handling and arrhythmogenic activity of pulmonary vein cardiomyocytes</article-title>
          <source>Br J Pharmacol</source>
          <year>2008</year>
          <volume>153</volume>
          <fpage>915</fpage>
          <lpage>925</lpage>
          <pub-id pub-id-type="pmid">17994112</pub-id>
        </element-citation>
      </ref>
      <ref id="R33">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carlsson</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Almgren</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Duker</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions</article-title>
          <source>J Cardiovasc Pharmacol</source>
          <year>1990</year>
          <volume>16</volume>
          <fpage>276</fpage>
          <lpage>285</lpage>
          <pub-id pub-id-type="pmid">1697384</pub-id>
        </element-citation>
      </ref>
      <ref id="R34">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Volders</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Vos</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Szabo</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Progress in the understanding of cardiac early afterdepolarizations and torsades de pointes: time to revise current concepts</article-title>
          <source>Cardiovasc Res</source>
          <year>2000</year>
          <volume>46</volume>
          <fpage>376</fpage>
          <lpage>392</lpage>
          <pub-id pub-id-type="pmid">10912449</pub-id>
        </element-citation>
      </ref>
      <ref id="R35">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carlsson</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title><italic>In vitro</italic> and <italic>in vivo</italic> models for testing arrhythmogenesis in drugs</article-title>
          <source>J Intern Med</source>
          <year>2006</year>
          <volume>259</volume>
          <fpage>70</fpage>
          <lpage>80</lpage>
          <pub-id pub-id-type="pmid">16336515</pub-id>
        </element-citation>
      </ref>
      <ref id="R36">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hasumi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Matsuda</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Shimamoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hata</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kaneko</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization</article-title>
          <source>Eur J Pharmacol</source>
          <year>2007</year>
          <volume>555</volume>
          <fpage>54</fpage>
          <lpage>60</lpage>
          <pub-id pub-id-type="pmid">17112502</pub-id>
        </element-citation>
      </ref>
      <ref id="R37">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aurigemma</surname>
              <given-names>GP</given-names>
            </name>
            <name>
              <surname>Gaasch</surname>
              <given-names>WH</given-names>
            </name>
          </person-group>
          <article-title>Clinical practice. Diastolic heart failure</article-title>
          <source>N Engl J Med</source>
          <year>2004</year>
          <volume>351</volume>
          <fpage>1097</fpage>
          <lpage>1105</lpage>
          <pub-id pub-id-type="pmid">15356307</pub-id>
        </element-citation>
      </ref>
      <ref id="R38">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gaasch</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Zile</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>Left ventricular diastolic dysfunction and diastolic heart failure</article-title>
          <source>Annu Rev Med</source>
          <year>2004</year>
          <volume>55</volume>
          <fpage>373</fpage>
          <lpage>394</lpage>
          <pub-id pub-id-type="pmid">14746527</pub-id>
        </element-citation>
      </ref>
      <ref id="R39">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Matsuda</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ohtani</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Arikawa</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Norepinephrine induces diastolic dysfunction in infarcted rats</article-title>
          <source>J Cardiac Failure</source>
          <year>2007</year>
          <volume>13</volume>
          <issue>S35</issue>
        </element-citation>
      </ref>
      <ref id="R40">
        <label>40</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Inagaki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kihara</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Izumi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sasayama</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>The cardioprotective effects of a new 1,4-benzothiazepine derivative, JTV519, on ischemia/reperfusion-induced Ca2+ overload in isolated rat hearts</article-title>
          <source>Cardiovasc Drugs Ther</source>
          <year>2000</year>
          <volume>14</volume>
          <fpage>489</fpage>
          <lpage>495</lpage>
          <pub-id pub-id-type="pmid">11101196</pub-id>
        </element-citation>
      </ref>
      <ref id="R41">
        <label>41</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ellison</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Torella</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Karakikes</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Acute beta-adrenergic overload produces myocyte damage through calcium leakage from the ryanodine receptor 2 but spares cardiac stem cells</article-title>
          <source>J Biol Chem</source>
          <year>2007</year>
          <volume>282</volume>
          <fpage>11397</fpage>
          <lpage>11409</lpage>
          <pub-id pub-id-type="pmid">17237229</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" position="float">
      <label>Fig. (1)</label>
      <caption>
        <p>Molecular structure of K201.</p>
      </caption>
      <graphic xlink:href="CCP-4-126_F1"/>
    </fig>
    <fig id="F2" position="float">
      <label>Fig. (2)</label>
      <caption>
        <p>Action sites of K201 on the cell membrane and in cells: &#x22A5;, inhibition; &#x2193;, activation; &#x21D3;, modulation. AC: adenylate cyclase, Ach: acetylcholine, An V: annexin V, AR: adrenoreceptor, Epi: epinephrine, FKBP: FK506 binding protein, G: G-protein, MLC: myosin light chain, M<sub>2</sub>-Rec: M<sub>2</sub>-muscarinic receptor, NCX: Na<sup>+</sup>/Ca<sup>2+</sup> exchanger, PKA: protein kinase A, PKC: protein kinase C, PLB: phospholamban, PLC: phospholipase C, PS: phosphatidylserine, NE: norepinephrine, RACK: receptor for activated C kinase, RyR2: ryanodine receptor 2, SR: sarcoplasmic reticulum, SERCA: SR Ca<sup>2+</sup>-ATPase, Tn: troponin.</p>
      </caption>
      <graphic xlink:href="CCP-4-126_F2"/>
    </fig>
    <fig id="F3" position="float">
      <label>Fig. (3)</label>
      <caption>
        <p>The crystal structure of annexin V and binding site of K201. The K201 molecule is shown as a space-filling model. Hinge regions are represented in yellow and domains I, II, II and IV are colored dark blue, magenta, orange and sky-blue, respectively [<xref ref-type="bibr" rid="R24">24</xref>].</p>
      </caption>
      <graphic xlink:href="CCP-4-126_F3"/>
    </fig>
    <fig id="F4" position="float">
      <label>Fig. (4)</label>
      <caption>
        <p>Amino acids of annexin V in the vicinity of bound K201. (<bold>a</bold>) The L-shaped K201 molecule interacts at the hinge 2 region. (<bold>b</bold>) The K201 binding site in stereo view [<xref ref-type="bibr" rid="R24">24</xref>].</p>
      </caption>
      <graphic xlink:href="CCP-4-126_F4"/>
    </fig>
    <fig id="F5" position="float">
      <label>Fig. (5)</label>
      <caption>
        <p>Simultaneous recording of ventricular and aortic pressure in rats. <bold>A</bold>) Before Ca<sup>2+</sup> loading, <bold>B</bold>) 20 minutes after norepinephrine administration with Ca<sup>2+</sup> loading, and <bold>C</bold>) 23 minutes after norepinephrine administration with Ca<sup>2+</sup> loading [<xref ref-type="bibr" rid="R28">28</xref>]. Diastolic contracture (B, arrow) was observed after norepinephrine administration with Ca<sup>2+</sup> loading, and subsequently the diastolic pressure exceeded the aortic pressure, resulting in opening of the aortic valve in the diastolic phase (C, arrow) [<xref ref-type="bibr" rid="R28">28</xref>]. K201 inhibits this diastolic contracture, but diltiazem does not do so [<xref ref-type="bibr" rid="R29">29</xref>]. The figure is modified from that shown in ref. 28.</p>
      </caption>
      <graphic xlink:href="CCP-4-126_F5"/>
    </fig>
  </floats-group>
</article>
